Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.74 |
| ▸ | TP53 | P04637 | 5/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.74 |
| ▸ | ATM | Q13315 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | APP | P05067 | 2/20 | 0.72 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3045361 | 0.91 | MAPT (0.61) | MAPTTP53LMNATSHRRAB9A | |
| SCHEMBL13291441 | 0.87 | MAPT (0.80) | MAPTTP53LMNATSHRRAB9A | |
| SCHEMBL11008472 | 0.86 | MAPT (0.78) | MAPTTP53LMNATSHRRAB9A | |
| SCHEMBL13394267 | 0.86 | MAPT (0.78) | MAPTTP53LMNATSHRRAB9A | |
| SCHEMBL772566 | 0.86 | MAPT (0.78) | MAPTTP53LMNATSHRRAB9A | |
| SCHEMBL3045412 | 0.86 | MAPT (0.78) | MAPTTP53LMNATSHRRAB9A | |
| Bromide SCHEMBL3867312 | 0.86 | MAPT (0.78) | MAPTTP53LMNATSHRRAB9A | |
| SCHEMBL13290939 | 0.86 | MAPT (0.78) | MAPTTP53LMNATSHRRAB9A | |
| SCHEMBL11015014 | 0.85 | TP53 (1.00) | MAPTTP53LMNATSHRRAB9A | |
| SCHEMBL13394273 | 0.84 | MAPT (0.74) | MAPTTP53LMNATSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100150833-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-17 | — | — | US | disclosed |
| US-20100143251-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100143253-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| EP-2023919-A2 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | Molecular Neuroimaging, LLC (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008118122-A2 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143253-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | APP, BACE1, BACE2 | MAPT 29/4885TP53 499/4885LMNA 481/4885 |
| US-20100150833-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | APP, BACE1, BACE2 | MAPT 29/4885TP53 499/4885LMNA 481/4885 |
| US-20100143251-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | APP, BACE1, BACE2 | MAPT 29/4885TP53 499/4885LMNA 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.